Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tauroursodeoxycholic acid + camrelizumab + tyrosine kinase inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is an investigational regimen being evaluated for the treatment of advanced hepatocellular carcinoma (HCC) following the failure of first-line therapy. It is a specific arm within the HCC-SIGHT platform trial, a Phase II Bayesian adaptive study led by Fudan University. The regimen consists of three components: tauroursodeoxycholic acid (TUDCA), an oral bile acid that may provide cytoprotection and reduce endoplasmic reticulum (ER) stress; camrelizumab, a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor; and a tyrosine kinase inhibitor (TKI), which in this trial is either lenvatinib or regorafenib. Lenvatinib and regorafenib are small molecule inhibitors that target multiple receptors involved in angiogenesis and tumor growth, such as VEGFR, FGFR, and PDGFR. The combination aims to leverage the synergistic potential of anti-angiogenic therapy and immunotherapy while utilizing TUDCA to potentially improve the safety profile or efficacy within the liver's unique metabolic environment.
- Brand names
- LenvimaStivarga
- Other names
- TUDCA + camrelizumab + TKItauroursodeoxycholic acid + camrelizumab + lenvatinibtauroursodeoxycholic acid + camrelizumab + regorafenib
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)Endoplasmic reticulum stress / unfolded protein response machineryFGFR4 (Fibroblast growth factor receptor 4)S1PR2 (S1P receptor 2)GPBAR1VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR1 (Fibroblast growth factor receptor 1)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on tauroursodeoxycholic acid + camrelizumab + tyrosine kinase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tauroursodeoxycholic acid + camrelizumab + tyrosine kinase inhibitor.